Finance
Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
Published by Global Banking & Finance Review®
Posted on February 25, 2026
2 min readLast updated: February 25, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 25, 2026
2 min readLast updated: February 25, 2026
Novo Nordisk partnered with U.S.-based Vivtex in a deal worth up to $2.1B to develop next-gen oral drugs for obesity and diabetes. Vivtex supplies gut-screening and AI delivery tech, while Novo leads development and commercialization.
Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and diabetes, the companies said on Wednesday.
Under the partnership, the privately held company will license some of its oral drug-delivery technology, while Novo Nordisk will take charge of global development and commercialization.
Here are some details:
* Novo Nordisk will make an undisclosed upfront payment toVivtex under the deal, besides milestone payments and royaltieson future product sales. * The partnership aims to make oral forms of biologic drugsthat would otherwise be given as injections by improving howthey are absorbed in the gut. * Vivtex's platform uses gut-screening tests, deliverytechnologies and AI tools to help make biologic drugs work aspills, the companies said. * Novo currently offers GLP-1 drugs for obesity and type 2diabetes, including Wegovy, Ozempic and the oral diabetes drugRybelsus. * In January, the Danish drugmaker launched Wegovy pill, theworld's first oral drug for obesity, in the U.S.(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)
Novo Nordisk has partnered with Vivtex in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and type 2 diabetes. Vivtex licenses its oral delivery technology while Novo leads development and commercialization.
Vivtex provides a platform that uses gut-screening tests, delivery technologies, and AI to improve absorption of biologic drugs in the GI tract, enabling effective oral formulations.
Vivtex receives an undisclosed upfront payment, with additional milestone payments and royalties tied to future product sales. Novo Nordisk oversees global clinical development and commercialization.
Explore more articles in the Finance category
